CN113853197A - 一种吸入溶液药物组合物及其制备方法 - Google Patents

一种吸入溶液药物组合物及其制备方法 Download PDF

Info

Publication number
CN113853197A
CN113853197A CN202080037401.8A CN202080037401A CN113853197A CN 113853197 A CN113853197 A CN 113853197A CN 202080037401 A CN202080037401 A CN 202080037401A CN 113853197 A CN113853197 A CN 113853197A
Authority
CN
China
Prior art keywords
indacaterol
pharmaceutical composition
sodium
citric acid
concentration
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CN202080037401.8A
Other languages
English (en)
Other versions
CN113853197B (zh
Inventor
张轩邈
毛华
周洋
邹孟玮
杨必坤
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sichuan Haisco Pharmaceutical Co Ltd
Original Assignee
Sichuan Haisco Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sichuan Haisco Pharmaceutical Co Ltd filed Critical Sichuan Haisco Pharmaceutical Co Ltd
Priority to CN202210936672.8A priority Critical patent/CN115337292A/zh
Priority to CN202210912500.7A priority patent/CN115998680A/zh
Publication of CN113853197A publication Critical patent/CN113853197A/zh
Application granted granted Critical
Publication of CN113853197B publication Critical patent/CN113853197B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4704—2-Quinolinones, e.g. carbostyril
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0078—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a nebulizer such as a jet nebulizer, ultrasonic nebulizer, e.g. in the form of aqueous drug solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/12—Aerosols; Foams
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Dispersion Chemistry (AREA)
  • Otolaryngology (AREA)
  • Inorganic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

一种吸入溶液药物组合物及其制备方法，所述组合物包含茚达特罗或其盐、pH调节剂和水，以及任选的渗透压调节剂、缓冲离子对，通过将各组分溶解于水中制得。该药物组合物适合于借助于雾化器而将活性物质形成气雾以在哮喘及COPD症状中以吸入方式对患者施用。

Description

PCT国内申请，说明书已公开。

Claims (18)

  1. PCT国内申请，权利要求书已公开。
CN202080037401.8A 2019-10-11 2020-10-12 一种吸入溶液药物组合物及其制备方法 Active CN113853197B (zh)

Priority Applications (2)

Application Number Priority Date Filing Date Title
CN202210936672.8A CN115337292A (zh) 2019-10-11 2020-10-12 一种吸入溶液药物组合物及其制备方法
CN202210912500.7A CN115998680A (zh) 2019-10-11 2020-10-12 一种吸入溶液药物组合物及其制备方法

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
CN201910948205 2019-10-11
CN2019109482055 2019-10-11
CN202010144174 2020-03-06
CN2020101441740 2020-03-06
PCT/CN2020/120348 WO2021068961A1 (zh) 2019-10-11 2020-10-12 一种吸入溶液药物组合物及其制备方法

Related Child Applications (2)

Application Number Title Priority Date Filing Date
CN202210912500.7A Division CN115998680A (zh) 2019-10-11 2020-10-12 一种吸入溶液药物组合物及其制备方法
CN202210936672.8A Division CN115337292A (zh) 2019-10-11 2020-10-12 一种吸入溶液药物组合物及其制备方法

Publications (2)

Publication Number Publication Date
CN113853197A true CN113853197A (zh) 2021-12-28
CN113853197B CN113853197B (zh) 2022-08-30

Family

ID=75436740

Family Applications (3)

Application Number Title Priority Date Filing Date
CN202210912500.7A Pending CN115998680A (zh) 2019-10-11 2020-10-12 一种吸入溶液药物组合物及其制备方法
CN202210936672.8A Pending CN115337292A (zh) 2019-10-11 2020-10-12 一种吸入溶液药物组合物及其制备方法
CN202080037401.8A Active CN113853197B (zh) 2019-10-11 2020-10-12 一种吸入溶液药物组合物及其制备方法

Family Applications Before (2)

Application Number Title Priority Date Filing Date
CN202210912500.7A Pending CN115998680A (zh) 2019-10-11 2020-10-12 一种吸入溶液药物组合物及其制备方法
CN202210936672.8A Pending CN115337292A (zh) 2019-10-11 2020-10-12 一种吸入溶液药物组合物及其制备方法

Country Status (3)

Country Link
CN (3) CN115998680A (zh)
TW (1) TW202114640A (zh)
WO (1) WO2021068961A1 (zh)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN115381774A (zh) * 2022-08-30 2022-11-25 立生医药(苏州)有限公司 包含长效吸入性类固醇和长效β2受体激动剂组合的药物制剂

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2614901A (en) * 2022-01-21 2023-07-26 Nanopharm Ltd Inhalable formulations
CN117679423A (zh) * 2022-09-05 2024-03-12 立生医药(苏州)有限公司 预防或治疗呼吸系统疾病的吸入用药物组合物

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103269694A (zh) * 2010-10-12 2013-08-28 西普拉有限公司 药物组合物
WO2019142214A1 (en) * 2018-01-19 2019-07-25 Cipla Limited Pharmaceutical composition comprising tiotropium for inhalation

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103860463B (zh) * 2014-03-11 2016-07-06 熊妲妮 一种含马来酸茚达特罗的溶液及其吸入喷雾剂
CN116173025A (zh) * 2018-07-26 2023-05-30 四川海思科制药有限公司 一种含格隆铵盐及茚达特罗盐的气雾剂药物组合物及其制备方法与应用
WO2020105012A1 (en) * 2018-11-22 2020-05-28 Glenmark Specialty S.A. Sterile compositions of indacaterol suitable for nebulization
US20200215051A1 (en) * 2019-01-03 2020-07-09 Glenmark Specialty S.A. Nebulization composition comprising tiotropium and indacaterol

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103269694A (zh) * 2010-10-12 2013-08-28 西普拉有限公司 药物组合物
WO2019142214A1 (en) * 2018-01-19 2019-07-25 Cipla Limited Pharmaceutical composition comprising tiotropium for inhalation

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN115381774A (zh) * 2022-08-30 2022-11-25 立生医药(苏州)有限公司 包含长效吸入性类固醇和长效β2受体激动剂组合的药物制剂

Also Published As

Publication number Publication date
WO2021068961A1 (zh) 2021-04-15
CN113853197B (zh) 2022-08-30
TW202114640A (zh) 2021-04-16
CN115337292A (zh) 2022-11-15
CN115998680A (zh) 2023-04-25

Similar Documents

Publication Publication Date Title
CN113853197B (zh) 一种吸入溶液药物组合物及其制备方法
US11052042B2 (en) Aqueous suspensions of ciclesonide for nebulisation
CZ285966B6 (cs) Prostředek ve formě suspenze a způsob jeho výroby
US8075873B2 (en) Method of preparing dry powder inhalation compositions
CN103582477A (zh) 包含芜地溴铵和皮质类固醇的组合
WO2016178019A1 (en) A stable tiotropium nebuliser solution
EP0338670B1 (en) Pharmaceutical Compositions
CN114053216A (zh) 一种吸入用芜地溴铵溶液制剂及其制备方法
CN117263848A (zh) 一种雷芬那辛的吸入喷雾剂
KR101728116B1 (ko) 티오트로피움 또는 이의 약학적으로 허용가능한 염을 함유하는 흡입용 건조분말 조성물
RU2611665C2 (ru) Улучшенный состав суспензии кортикостероида для ингаляционного введения
US20050158248A1 (en) Method of preparing dry powder inhalation compositions
CN111789827A (zh) 一种硫酸依替米星雾化吸入用制剂及其制备方法
CN117838671A (zh) 一种含维兰特罗的吸入溶液药物组合物及其制备方法
CN115337311B (zh) 一种治疗呼吸系统疾病的组合物及其制备方法
CN111297835B (zh) 含抗胆碱能药物的吸入气雾剂及其制备工艺和使用方法
CN114642656A (zh) 一种吸入用尼达尼布溶液及其制备方法
AU2015328153A1 (en) Formulations containing tiotropium, amino acid and acid and methods thereof
WO2022166724A1 (zh) 一种福多司坦吸入用溶液制剂及其制备方法和用途
WO2022231533A1 (en) Process for the preparation of sterilized suspensions for the inhalation by nebulization
CN114073684A (zh) 三苯乙酸维兰特罗吸入溶液及其制备方法
CN115137713A (zh) 一种两性霉素b雾化吸入制剂及其制备方法
CN114515279A (zh) 一种安立生坦雾化吸入溶液及其制备方法
CN117064869A (zh) 一种胶囊型吸入粉雾剂及其制备方法
CN117679423A (zh) 预防或治疗呼吸系统疾病的吸入用药物组合物

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant